224 related articles for article (PubMed ID: 25538895)
1. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity.
Vandamme N; Berx G
Front Oncol; 2014; 4():352. PubMed ID: 25538895
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression.
Bruneel K; Verstappe J; Vandamme N; Berx G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796736
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.
Kim JE; Leung E; Baguley BC; Finlay GJ
Front Genet; 2013; 4():97. PubMed ID: 23755070
[TBL] [Abstract][Full Text] [Related]
4. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment.
Tang Y; Durand S; Dalle S; Caramel J
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759677
[TBL] [Abstract][Full Text] [Related]
5. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.
Caramel J; Papadogeorgakis E; Hill L; Browne GJ; Richard G; Wierinckx A; Saldanha G; Osborne J; Hutchinson P; Tse G; Lachuer J; Puisieux A; Pringle JH; Ansieau S; Tulchinsky E
Cancer Cell; 2013 Oct; 24(4):466-80. PubMed ID: 24075834
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
7. Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis.
Pillai M; Rajaram G; Thakur P; Agarwal N; Muralidharan S; Ray A; Barbhaya D; Somarelli JA; Jolly MK
Front Oncol; 2022; 12():913803. PubMed ID: 36003764
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
Pearlman RL; Montes de Oca MK; Pal HC; Afaq F
Cancer Lett; 2017 Apr; 391():125-140. PubMed ID: 28131904
[TBL] [Abstract][Full Text] [Related]
9. A Theoretical Model of the Wnt Signaling Pathway in the Epithelial Mesenchymal Transition.
Gasior K; Hauck M; Wilson A; Bhattacharya S
Theor Biol Med Model; 2017 Oct; 14(1):19. PubMed ID: 28992816
[TBL] [Abstract][Full Text] [Related]
10. NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.
Huergo-Zapico L; Parodi M; Cantoni C; Lavarello C; Fernández-Martínez JL; Petretto A; DeAndrés-Galiana EJ; Balsamo M; López-Soto A; Pietra G; Bugatti M; Munari E; Marconi M; Mingari MC; Vermi W; Moretta L; González S; Vitale M
Cancer Res; 2018 Jul; 78(14):3913-3925. PubMed ID: 29752261
[TBL] [Abstract][Full Text] [Related]
11. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
12. Tumoral and stromal expression of Slug, ZEB1, and ZEB2 in brain metastasis.
Nagaishi M; Nakata S; Ono Y; Hirata K; Tanaka Y; Suzuki K; Yokoo H; Hyodo A
J Clin Neurosci; 2017 Dec; 46():124-128. PubMed ID: 28890036
[TBL] [Abstract][Full Text] [Related]
13. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
14. Bone Morphogenic Protein Signaling and Melanoma.
Kraj P
Curr Treat Options Oncol; 2021 Apr; 22(6):48. PubMed ID: 33866453
[TBL] [Abstract][Full Text] [Related]
15. Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity.
Jain P; Pillai M; Duddu AS; Somarelli JA; Goyal Y; Jolly MK
Semin Cancer Biol; 2023 Nov; 96():48-63. PubMed ID: 37788736
[TBL] [Abstract][Full Text] [Related]
16. EMT-associated factors promote invasive properties of uveal melanoma cells.
Asnaghi L; Gezgin G; Tripathy A; Handa JT; Merbs SL; van der Velden PA; Jager MJ; Harbour JW; Eberhart CG
Mol Vis; 2015; 21():919-29. PubMed ID: 26321866
[TBL] [Abstract][Full Text] [Related]
17. The transcription factor LEF-1 induces an epithelial-mesenchymal transition in MDCK cells independent of β-catenin.
Kobayashi W; Ozawa M
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):133-8. PubMed ID: 24269234
[TBL] [Abstract][Full Text] [Related]
18. Roles of the Phosphorylation of Transcriptional Factors in Epithelial-Mesenchymal Transition.
Xu R; Won JY; Kim CH; Kim DE; Yim H
J Oncol; 2019; 2019():5810465. PubMed ID: 31275381
[TBL] [Abstract][Full Text] [Related]
19. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient?
Krasnapolski MA; Todaro LB; de Kier Joffé EB
Curr Pharm Biotechnol; 2011 Nov; 12(11):1891-9. PubMed ID: 21470129
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.
Imani S; Wei C; Cheng J; Khan MA; Fu S; Yang L; Tania M; Zhang X; Xiao X; Zhang X; Fu J
Oncotarget; 2017 Mar; 8(13):21362-21379. PubMed ID: 28423483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
